However, many cancer cells are resistant to DRs-mediated apoptosis due to a variety of mechanisms, and this is the reason for the low antitumor activity of its various therapeutic agonists (recombinant TRAIL variants or antibodies to receptors) in clinical trials (Micheau et al., 2013; Kretz et al., 2019). The gene discussed is TNFSF10; the disease is cancer.